# Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/dapagliflozin-a-novel-sglt2-inhibitor-induces-dose-dependent-glucosuria-in/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Bernard J. Komoroski,N. Vachharajani,David W. Boulton,David M. Kornhauser,Margarida Geraldes,L Li,Marc Pfister |
| Citations | 348 |
| DOI | 10.1038/clpt.2008.251 |
| Fields | Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1038/clpt.2008.251 |
| OpenAlex ID | https://openalex.org/W2149973065 |
| PMID | 19129748 |
| Type | article |
| Year | 2009 |

## Paper authors

- [David W. Boulton](https://scholariq.org/researchers/david-w-boulton/)

## Paper primary topic

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Paper topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)
- [Pharmacology and Obesity Treatment](https://scholariq.org/topics/pharmacology-and-obesity-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.